
    
      The sponsor and the study steering committee decided to prematurely stop enrollment of
      subjects to Arm 1 after data review showed an increased treatment discontinuation rate due to
      progressive disease in Arm 1 as compared to Arms 2 and 3 (both containing Carboplatin).
    
  